Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-09
2005-08-09
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S314000, C514S342000, C514S372000, C544S003000, C546S172000, C546S271100, C548S111000, C548S206000, C548S213000, C548S214000
Reexamination Certificate
active
06927216
ABSTRACT:
The present application describes novel cyclic sulfonyl derivatives of formula I:or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.
REFERENCES:
patent: 780386 (1997-06-01), None
patent: 818442 (1998-01-01), None
patent: 1004578 (2000-05-01), None
patent: WO 9720824 (1997-06-01), None
patent: WO 9941246 (1999-08-01), None
patent: WO 9958531 (1999-11-01), None
patent: WO 9965867 (1999-12-01), None
CAPLUS printout for EP 0 342 456, Nov. 23, 1989.
Luisi, G. et al, Pseudopeptides containing isothiazolidine-1, 1-dioxide-3-carboxylic acid: synthesis and properties of (S)-isothiazolidine-1,1-dioxide-3-carboxylic acid, a new gamma-sultam analog of pyroglutamic acid, Archiv. Der. Pharmazie, vol. 326, no 3, 1993, pp. 139-141.
Cherney Robert J.
King Bryan W.
Bristol-Myers Squibb Pharma Company
Coleman Brenda
Sam Jing G.
Vance David H.
LandOfFree
Cyclic sulfonyl compounds as inhibitors of metalloproteases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic sulfonyl compounds as inhibitors of metalloproteases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic sulfonyl compounds as inhibitors of metalloproteases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497505